| [1] |
Koboldt DC, Steinberg KM, Larson DE, et al. The next-generation sequencing revolution and its impact on genomics[J]. Cell, 2013,155(1):27-38.
|
| [2] |
Agostini M, Pucciarelli S, Enzo MV, et al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy[J]. Ann Surg Oncol, 2011,18(9):2461-2468.
|
| [3] |
Zhou J, Chang L, Guan Y, et al. Application of circulating tumor DNA as a non-invasive tool for monitoring the progression of colorectal cancer[J]. PLoS One, 2016,11(7):e0159708.
|
| [4] |
Spellman PT, Gray JW. Detecting cancer by monitoring circulating tumor DNA[J]. Nat Med, 2014,20(5):474-475.
|
| [5] |
Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer[J]. Clin Cancer Res, 2014,20(10):2643-2650.
|
| [6] |
Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples[J]. Nat Biotechnol, 2013,31(3):213-219.
|
| [7] |
Li J, Lupat R, Amarasinghe KC, et al. CONTRA: copy number analysis for targeted resequencing[J]. Bioinformatics, 2012,28(10):1307-1313.
|
| [8] |
Roth A, Khattra J, Yap D, et al. PyClone: statistical inference of clonal population structure in cancer[J]. Nat Methods, 2014,11(4):396-398.
|
| [9] |
Nakayama N, Nakayama K, Yeasmin S, et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer[J]. Br J Cancer, 2008,99(12):2020-2028.
|
| [10] |
Gasch C, Oldopp T, Mauermann O, et al. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer[J]. Mol Oncol, 2016,10(8):1330-1343.
|
| [11] |
Murtaza M, Dawson SJ, Pogrebniak K, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer[J]. Nat Commun, 2015,6:8760.
|
| [12] |
O’leary B, Hrebien S, Morden JP, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer[J]. Nat Commun, 2018,9(1):896.
|
| [13] |
McGranahan N, Favero F, de Bruin EC, et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution[J]. Sci Transl Med, 2015,7(283):283ra54.
|
| [14] |
Yi Z, Ma F. Biomarkers of everolimus sensitivity in hormone receptor-positive breast cancer[J]. J Breast Cancer, 2017,20(4):321-326.
|
| [15] |
Wang L, Zhang Q, Zhang J, et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib[J]. BMC Cancer, 2011,11:248.
|
| [16] |
Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol, 2017,14(9):531-548.
|
| [17] |
Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors[J]. Bull Cancer, 2000,87(12):881-886.
|
| [18] |
Chung JH, Pavlick D, Hartmaier R, et al. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer[J]. Ann Oncol, 2017,28(11):2866-2873.
|